Evozyne
Uri Herzberg currently serves as Chief Drug Discovery Officer at Evozyne since September 2023. Prior to this position, Uri was VP and Head of Translational Research at Fresh Tracks Therapeutics and held various leadership roles at Cabaletta Bio, Celularity, Inc., Celgene, Johnson & Johnson, Neurogen Corporation, Acorda Therapeutics, Cytotherapeutics, and the NIH. Expertise includes inflammation, pain, immune disorders, and neuroscience, with significant involvement in drug discovery and translational research. Academic credentials include a DVM from Washington State University, an MBA in Pharmaceutical Development from Fairleigh Dickinson University, and a PhD in Veterinary Biology and Neuroimmunology from the University of Minnesota.
This person is not in any offices
Evozyne
1 followers
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.